ulcerative colitis and tirzepatide Five Things to Know About Weight-Loss Drugs IBD Ulcerative Colitis and Weight Loss:

Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin

Dehydration can mimic hunger

FIGURE 6 3.4.3 The proportion of participants achieving weight loss of more than 5, 10, 15, and 20% Five studies (Wilding et al., 2021

She has regained 20 lb, and her polycystic ovarian syndrome symptoms, which had disappeared with weight loss, are returning